Contact
searchSearch
HMP Global
Login

Small-Cell Lung Cancer Specialty Channel

Deborah Doroshow, MD, PhD
Conference Coverage
Immunotherapy for Patients With Small Cell Lung Cancer
03/27/2025
Deborah Doroshow, MD, PhD
Deborah Doroshow, MD, PhD, discusses the role of immunotherapy when treating patients with small cell lung cancer.
Deborah Doroshow, MD, PhD, discusses the role of immunotherapy when treating patients with small cell lung cancer.
Deborah Doroshow, MD, PhD,...
03/27/2025
Oncology
Quiz
Central Nervous System Progression in Extensive-Stage Small Cell Lung Cancer
03/19/2025
Did atezolizumab plus etoposide and carboplatin delay time to central nervous system progression among patients with extensive-stage small cell lung cancer?
Did atezolizumab plus etoposide and carboplatin delay time to central nervous system progression among patients with extensive-stage small cell lung cancer?
Did atezolizumab plus etoposide...
03/19/2025
Oncology
News
Atezolizumab Plus Etoposide and Carboplatin Delays CNS Progression for Patients With Extensive-Stage Small Cell Lung Cancer
03/11/2025
Stephanie Holland
According to results from a retrospective, real-world study, atezolizumab plus etoposide and carboplatin delayed time to central nervous system progression among patients with extensive-stage small cell lung cancer.
According to results from a retrospective, real-world study, atezolizumab plus etoposide and carboplatin delayed time to central nervous system progression among patients with extensive-stage small cell lung cancer.
According to results from a...
03/11/2025
Oncology
Quiz
Talazoparib Plus Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
03/05/2025
According to results from the phase 2 SWOG S1929 study, what was the result of adding talazoparib to maintenance atezolizumab among patients with extensive-stage small cell lung cancer?
According to results from the phase 2 SWOG S1929 study, what was the result of adding talazoparib to maintenance atezolizumab among patients with extensive-stage small cell lung cancer?
According to results from the...
03/05/2025
Oncology
Nagla Abdel Karim, MD, PhD
Videos
Maintenance Talazoparib Plus Atezolizumab for Patients With SLFN11-Positive Extensive-Stage Small Cell Lung Cancer
02/25/2025
Nagla Abdel Karim, MD
Nagla Abdel Karim, MD, PhD, discusses phase 2 study results which demonstrated that the addition of talazoparib to maintenance atezolizumab improved survival outcomes for patients with SLFN11-positive extensive-stage small cell lung cancer.
Nagla Abdel Karim, MD, PhD, discusses phase 2 study results which demonstrated that the addition of talazoparib to maintenance atezolizumab improved survival outcomes for patients with SLFN11-positive extensive-stage small cell lung cancer.
Nagla Abdel Karim, MD, PhD,...
02/25/2025
Oncology
News
Efficacy, Safety of Lurbinectedin Plus Pembrolizumab for Patients With Relapsed Small Cell Lung Cancer
02/19/2025
Stephanie Holland
According to results from the phase 1/2 LUPER study, lurbinectedin plus pembrolizumab demonstrated promise among immunotherapy-naive patients with relapsed small cell lung cancer.
According to results from the phase 1/2 LUPER study, lurbinectedin plus pembrolizumab demonstrated promise among immunotherapy-naive patients with relapsed small cell lung cancer.
According to results from the...
02/19/2025
Oncology
Quiz
Lurbinectedin for Patients With Platinum-Sensitive Small Cell Lung Cancer
02/10/2025
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate...
02/10/2025
Oncology
News
Second-Line Sacituzumab Govitecan Shows Promise for Extensive-Stage Small Cell Lung Cancer
02/05/2025
Stephanie Holland
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated promise as a second-line option for patients with extensive-stage small cell lung cancer.
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated promise as a second-line option for patients with extensive-stage small cell lung cancer.
According to results from the...
02/05/2025
Oncology
Quiz
Trilaciclib for Patients With Extensive-Stage Small Cell Lung Cancer
01/22/2025
Did the administration of trilaciclib prior to chemotherapy reduce the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer?
Did the administration of trilaciclib prior to chemotherapy reduce the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer?
Did the administration of...
01/22/2025
Oncology
News
Trilaciclib Reduces Chemotherapy-Induced Myelosuppression for Extensive-Stage Small Cell Lung Cancer
01/22/2025
Stephanie Holland
Results from a pooled analysis demonstrated the administration of trilaciclib prior to chemotherapy reduced the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer.
Results from a pooled analysis demonstrated the administration of trilaciclib prior to chemotherapy reduced the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer.
Results from a pooled analysis...
01/22/2025
Oncology
News
Lurbinectedin Demonstrates Promise As Second-Line Option for Patients With Platinum-Sensitive Small Cell Lung Cancer
12/18/2024
Stephanie Holland
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse after platinum-based treatment.
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse after platinum-based treatment.
Retrospective analysis results...
12/18/2024
Oncology

News

Deborah Doroshow, MD, PhD
Conference Coverage
Immunotherapy for Patients With Small Cell Lung Cancer
03/27/2025
Deborah Doroshow, MD, PhD
Deborah Doroshow, MD, PhD, discusses the role of immunotherapy when treating patients with small cell lung cancer.
Deborah Doroshow, MD, PhD, discusses the role of immunotherapy when treating patients with small cell lung cancer.
Deborah Doroshow, MD, PhD,...
03/27/2025
Oncology
News
Atezolizumab Plus Etoposide and Carboplatin Delays CNS Progression for Patients With Extensive-Stage Small Cell Lung Cancer
03/11/2025
Stephanie Holland
According to results from a retrospective, real-world study, atezolizumab plus etoposide and carboplatin delayed time to central nervous system progression among patients with extensive-stage small cell lung cancer.
According to results from a retrospective, real-world study, atezolizumab plus etoposide and carboplatin delayed time to central nervous system progression among patients with extensive-stage small cell lung cancer.
According to results from a...
03/11/2025
Oncology
News
Efficacy, Safety of Lurbinectedin Plus Pembrolizumab for Patients With Relapsed Small Cell Lung Cancer
02/19/2025
Stephanie Holland
According to results from the phase 1/2 LUPER study, lurbinectedin plus pembrolizumab demonstrated promise among immunotherapy-naive patients with relapsed small cell lung cancer.
According to results from the phase 1/2 LUPER study, lurbinectedin plus pembrolizumab demonstrated promise among immunotherapy-naive patients with relapsed small cell lung cancer.
According to results from the...
02/19/2025
Oncology
News
Second-Line Sacituzumab Govitecan Shows Promise for Extensive-Stage Small Cell Lung Cancer
02/05/2025
Stephanie Holland
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated promise as a second-line option for patients with extensive-stage small cell lung cancer.
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated promise as a second-line option for patients with extensive-stage small cell lung cancer.
According to results from the...
02/05/2025
Oncology
News
Trilaciclib Reduces Chemotherapy-Induced Myelosuppression for Extensive-Stage Small Cell Lung Cancer
01/22/2025
Stephanie Holland
Results from a pooled analysis demonstrated the administration of trilaciclib prior to chemotherapy reduced the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer.
Results from a pooled analysis demonstrated the administration of trilaciclib prior to chemotherapy reduced the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer.
Results from a pooled analysis...
01/22/2025
Oncology
News
Lurbinectedin Demonstrates Promise As Second-Line Option for Patients With Platinum-Sensitive Small Cell Lung Cancer
12/18/2024
Stephanie Holland
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse after platinum-based treatment.
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse after platinum-based treatment.
Retrospective analysis results...
12/18/2024
Oncology
News
Chemoimmunotherapy Demonstrates Real-World Long-Term Efficacy for Patients With Extensive-Stage Small Cell Lung Cancer
12/10/2024
Stephanie Holland
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to results from a...
12/10/2024
Oncology
News
FDA Approves Durvalumab for Patients With Limited-Stage Small Cell Lung Cancer
12/05/2024
Stephanie Holland
Based on results from the ADRIATIC trial, the FDA has approved durvalumab for adult patients with limited-stage small cell lung cancer who have not experienced disease progression following concurrent platinum-based chemotherapy and...
Based on results from the ADRIATIC trial, the FDA has approved durvalumab for adult patients with limited-stage small cell lung cancer who have not experienced disease progression following concurrent platinum-based chemotherapy and...
Based on results from the...
12/05/2024
Oncology
News
Addition of Talazoparib to Maintenance Atezolizumab Improves Survival Outcomes for Patients With SLFN11-Positive Extensive-Stage Small Cell Lung Cancer
12/04/2024
Stephanie Holland
Phase 2 study results demonstrated the addition of talazoparib to maintenance atezolizumab improved survival outcomes for patients with SLFN11-positive extensive-stage small cell lung cancer.
Phase 2 study results demonstrated the addition of talazoparib to maintenance atezolizumab improved survival outcomes for patients with SLFN11-positive extensive-stage small cell lung cancer.
Phase 2 study results...
12/04/2024
Oncology
News
Addition of Toripalimab to First-Line Chemotherapy Improves Survival for Patients With Extensive-Stage Small Cell Lung Cancer
11/19/2024
Stephanie Holland
Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.
Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.
Results from the phase 3...
11/19/2024
Oncology

Interactive Features

Quiz
Central Nervous System Progression in Extensive-Stage Small Cell Lung Cancer
03/19/2025
Did atezolizumab plus etoposide and carboplatin delay time to central nervous system progression among patients with extensive-stage small cell lung cancer?
Did atezolizumab plus etoposide and carboplatin delay time to central nervous system progression among patients with extensive-stage small cell lung cancer?
Did atezolizumab plus etoposide...
03/19/2025
Oncology
Quiz
Talazoparib Plus Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
03/05/2025
According to results from the phase 2 SWOG S1929 study, what was the result of adding talazoparib to maintenance atezolizumab among patients with extensive-stage small cell lung cancer?
According to results from the phase 2 SWOG S1929 study, what was the result of adding talazoparib to maintenance atezolizumab among patients with extensive-stage small cell lung cancer?
According to results from the...
03/05/2025
Oncology
Quiz
Lurbinectedin for Patients With Platinum-Sensitive Small Cell Lung Cancer
02/10/2025
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate...
02/10/2025
Oncology
Quiz
Trilaciclib for Patients With Extensive-Stage Small Cell Lung Cancer
01/22/2025
Did the administration of trilaciclib prior to chemotherapy reduce the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer?
Did the administration of trilaciclib prior to chemotherapy reduce the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer?
Did the administration of...
01/22/2025
Oncology
Quiz
Quiz: Standard of Care for Patients With Small Cell Lung Cancer
11/30/2022
What is the current treatment for patients with small cell lung cancer?
What is the current treatment for patients with small cell lung cancer?
What is the current treatment...
11/30/2022
Oncology
Quiz
True or False: Median PFS of patients with SCLC with inflamed tumors receiving ICI and chemotherapy double that of patients with noninflamed tumors.
11/09/2022
According to a retrospective study, how did the median PFS of patients with extensive stage SCLC receiving immune checkpoint inhibition and chemotherapy who had inflamed tumors compare to those patients with noninflamed tumors?
According to a retrospective study, how did the median PFS of patients with extensive stage SCLC receiving immune checkpoint inhibition and chemotherapy who had inflamed tumors compare to those patients with noninflamed tumors?
According to a retrospective...
11/09/2022
Oncology
Quiz
True or False: PD-1 and PD-L1 inhibitors can be utilized as treatment in almost all stages of small-cell lung cancer (SCLC)?
09/30/2022
Can PD-1 and PD-L1 inhibitors be used to treat small-cell lung cancer in addition to non-small cell lung cancer?
Can PD-1 and PD-L1 inhibitors be used to treat small-cell lung cancer in addition to non-small cell lung cancer?
Can PD-1 and PD-L1 inhibitors be...
09/30/2022
Oncology
Quiz
Quiz: Durvalumab Plus Concurrent Chemoradiation Among PD-L1 Positive Patients With SCLC
08/29/2022
Among patients with limited-stage SCLC, did patients in the PD-L1 positivity group of a phase 2 study published in the European Journal of Cancer experience longer PFS and OS vs patients who were PD-L1 negative when treated with durvalumab...
Among patients with limited-stage SCLC, did patients in the PD-L1 positivity group of a phase 2 study published in the European Journal of Cancer experience longer PFS and OS vs patients who were PD-L1 negative when treated with durvalumab...
Among patients with...
08/29/2022
Oncology
Quiz
Quiz: Current First-Line Standard of Care for Extensive-Stage SCLC
07/25/2022
What treatment option in addition to platinum-based chemotherapy has become the current standard of care in the first-line setting for patients with extensive-stage small-cell lung cancer?
What treatment option in addition to platinum-based chemotherapy has become the current standard of care in the first-line setting for patients with extensive-stage small-cell lung cancer?
What treatment option in...
07/25/2022
Oncology
Quiz
Quiz: Does Next-Generation BAP1 Therapy Inhibit SCLC Cell Viability and Tumor Growth?
07/20/2022
According to study findings, does the recently developed therapy targeting SCLC BAP1 activity iBAP-II inhibit SCLC cell viability and tumor growth in vivo?
According to study findings, does the recently developed therapy targeting SCLC BAP1 activity iBAP-II inhibit SCLC cell viability and tumor growth in vivo?
According to study findings,...
07/20/2022
Oncology

Recent News

News
Atezolizumab Plus Etoposide and Carboplatin Delays CNS Progression for Patients With Extensive-Stage Small Cell Lung Cancer
03/11/2025
Stephanie Holland
According to results from a retrospective, real-world study, atezolizumab plus etoposide and carboplatin delayed time to central nervous system progression among patients with extensive-stage small cell lung cancer.
According to results from a retrospective, real-world study, atezolizumab plus etoposide and carboplatin delayed time to central nervous system progression among patients with extensive-stage small cell lung cancer.
According to results from a...
03/11/2025
Oncology
News
Efficacy, Safety of Lurbinectedin Plus Pembrolizumab for Patients With Relapsed Small Cell Lung Cancer
02/19/2025
Stephanie Holland
According to results from the phase 1/2 LUPER study, lurbinectedin plus pembrolizumab demonstrated promise among immunotherapy-naive patients with relapsed small cell lung cancer.
According to results from the phase 1/2 LUPER study, lurbinectedin plus pembrolizumab demonstrated promise among immunotherapy-naive patients with relapsed small cell lung cancer.
According to results from the...
02/19/2025
Oncology
News
Second-Line Sacituzumab Govitecan Shows Promise for Extensive-Stage Small Cell Lung Cancer
02/05/2025
Stephanie Holland
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated promise as a second-line option for patients with extensive-stage small cell lung cancer.
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated promise as a second-line option for patients with extensive-stage small cell lung cancer.
According to results from the...
02/05/2025
Oncology
News
Trilaciclib Reduces Chemotherapy-Induced Myelosuppression for Extensive-Stage Small Cell Lung Cancer
01/22/2025
Stephanie Holland
Results from a pooled analysis demonstrated the administration of trilaciclib prior to chemotherapy reduced the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer.
Results from a pooled analysis demonstrated the administration of trilaciclib prior to chemotherapy reduced the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer.
Results from a pooled analysis...
01/22/2025
Oncology
News
Lurbinectedin Demonstrates Promise As Second-Line Option for Patients With Platinum-Sensitive Small Cell Lung Cancer
12/18/2024
Stephanie Holland
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse after platinum-based treatment.
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse after platinum-based treatment.
Retrospective analysis results...
12/18/2024
Oncology
News
Chemoimmunotherapy Demonstrates Real-World Long-Term Efficacy for Patients With Extensive-Stage Small Cell Lung Cancer
12/10/2024
Stephanie Holland
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to results from a real-world analysis, chemoimmunotherapy demonstrated long-term efficacy among patients with extensive-stage small cell lung cancer.
According to results from a...
12/10/2024
Oncology
News
FDA Approves Durvalumab for Patients With Limited-Stage Small Cell Lung Cancer
12/05/2024
Stephanie Holland
Based on results from the ADRIATIC trial, the FDA has approved durvalumab for adult patients with limited-stage small cell lung cancer who have not experienced disease progression following concurrent platinum-based chemotherapy and...
Based on results from the ADRIATIC trial, the FDA has approved durvalumab for adult patients with limited-stage small cell lung cancer who have not experienced disease progression following concurrent platinum-based chemotherapy and...
Based on results from the...
12/05/2024
Oncology
News
Addition of Talazoparib to Maintenance Atezolizumab Improves Survival Outcomes for Patients With SLFN11-Positive Extensive-Stage Small Cell Lung Cancer
12/04/2024
Stephanie Holland
Phase 2 study results demonstrated the addition of talazoparib to maintenance atezolizumab improved survival outcomes for patients with SLFN11-positive extensive-stage small cell lung cancer.
Phase 2 study results demonstrated the addition of talazoparib to maintenance atezolizumab improved survival outcomes for patients with SLFN11-positive extensive-stage small cell lung cancer.
Phase 2 study results...
12/04/2024
Oncology
News
Addition of Toripalimab to First-Line Chemotherapy Improves Survival for Patients With Extensive-Stage Small Cell Lung Cancer
11/19/2024
Stephanie Holland
Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.
Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.
Results from the phase 3...
11/19/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
Stephanie Holland
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
Stephanie Holland
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
FDA Approval
FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs
03/26/2025
Stephanie Holland
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the...
03/26/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use